Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04002102 · ClinicalTrials.gov registry record · NA
Open-Label Placebos to Treat Fatigue in Multiple Sclerosis
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
NCT04002102 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 48 participants.
The verdict
NCT04002102, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
Study Summary
Fatigue is one of the most prevalent and disabling symptoms of multiple sclerosis. Current treatments, including pharmacological, physical therapy, sleep regulation and psychological interventions are of marginal benefit. Pharmacological treatments have inconsistent evidence. Recent studies show that non-deceptive open-label placebos (OLP) have moderate-to-large effects on symptoms, including fatigue, in adults with a variety of medical conditions. Hence, this is a pilot and feasibility study to obtain data on the feasibility and effects of OLP for multiple sclerosis related fatigue and its impact to provide the basis for a competitive NIH application. This pilot study will be the first study to evaluate whether OLP, that garners full consent and engages patients in their wellness, may offer a safe, effective treatment for multiple sclerosis related fatigue.
Interventions
- OTHER Usual care
- OTHER OLP treatment
- OTHER Expectancy Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-02-17 |
| Est. Completion | 2022-01-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04002102
The ClinicalTrials.gov registry entry for NCT04002102 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Usual care is the first listed.
NCT04002102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04002102 about?
NCT04002102 is a clinical study titled "Open-Label Placebos to Treat Fatigue in Multiple Sclerosis". Fatigue is one of the most prevalent and disabling symptoms of multiple sclerosis. Current treatments, including pharmacological, physical therapy, sleep regulation and psychological interventions are of marginal benefit. Pharmacological treatments have inconsistent evidence. Recent studies show tha...
What is the current status of trial NCT04002102?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2020-02-17. Estimated completion is 2022-01-19.
What interventions are being tested in trial NCT04002102?
The interventions under investigation include: Usual care (OTHER), OLP treatment (OTHER), Expectancy Group (OTHER).
Who is sponsoring clinical trial NCT04002102?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.